

55

International Appl. No. PCT/EP2004/005881

-37-

4. A compound of formula I in accordance with claim 3, wherein R³ is unsubstituted or substituted 5 or 6 membered-heteroaryl and the substitution is selected from fluoro, CF₃ and C₁-C₆-alkyl.

5. A compound of formula I in accordance with claim 4, wherein the compounds are

2-[4-(2-chloro-pyridin-4-ylethynyl)-2-methyl-imidazol-1-yl]-4-trifluoromethyl-pyrimidine,
2-[4-(2-chloro-pyridin-4-ylethynyl)-2-methyl-imidazol-1-yl]-pyrazine,
2-[4-(2-chloro-pyridin-4-ylethynyl)-2-methyl-imidazol-1-yl]-6-trifluoromethyl-pyridine,
3-[4-(2-chloro-pyridin-4-ylethynyl)-2-methyl-imidazol-1-yl]-5-fluoro-pyridine,
4-[4-(2-chloro-pyridin-4-ylethynyl)-2-methyl-imidazolyl-1-yl]-2-trifluoromethyl-pyrimidine,
2-[4-(2-Chloro-pyridin-4-ylethynyl)-2-methyl-imidazolyl-1-yl]-6-methyl-4-trifluoromethyl-pyridine or
2-[4-(2-Chloro-pyridin-4-ylethynyl)-2-methyl-imidazolyl-1-yl]-5-methyl-pyridine.

6. A compound of formula I in accordance with claim 3, wherein R³ is phenyl, substituted by one or more halogen.

7. A compound of formula I in accordance with claim 6, wherein the compounds are

2-chloro-4-[1-(4-fluoro-phenyl)-2-methyl-1H-imidazol-4-ylethynyl]-pyridine,
2-fluoro-4-[1-(4-fluoro-phenyl)-2-methyl-1H-imidazol-4-ylethynyl]-pyridine,
2-Chloro-4-[1-(3,5-difluoro-phenyl)-2-methyl-1H-imidazol-4-ylethynyl]-pyridine,
2-Chloro-4-[1-(3,5-difluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine,
2-Chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine, or
2-chloro-4-[1-(3,5-difluoro-4-methyl-phenyl)-2-methyl-1H-imidazol-4-ylethynyl]-pyridine.

8. A process for preparing a compound of formula I as defined in claims 1 to 7, which process comprises reacting

(a) a compound of formula II

VB/IG 31.03.2005


AMENDED SHEET

04/04/2005

56

International Appl. No. PCT/EP2004/005881

-38-



(II)


wherein R^1 , R^2 and R^4 have the meanings as defined in claim 1,
with a compound of formula III



(III)


wherein R^3 has the meanings as defined in claim 1 and Z is halogen or $B(OH)_2$;
or reacting

(b) a compound of formula IV



(IV)


wherein R^2 , R^3 and R^4 have the meanings as defined in claim 1,
with a compound of formula V



(V)

wherein R^1 has the meanings as defined in claim 1 and X is halogen;
or reacting

(c) a compound of formula VI



(VI)

wherein R^2 , R^3 and R^4 have the meanings as defined in claim 1 and hal is halogen,

VB/IG 31.03.2005

AMENDED SHEET


04/04/2005

59

International Appl. No. PCT/EP2004/005881

-39-

with a compound of formula VII




(VII)

wherein R^1 has the meaning as defined in claim 1, and Y is trimethylsilyl or hydrogen, and if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.

9. A process for preparing a compound of formula I as defined in claims 1 to 7, which process comprises:

a) reacting a compound of formula




II

with a compound of formula R^3Z

III

wherein R_3 has the meanings as defined above and Z is halogen or $B(OH)_2$,

to a compound of formula



IA

VB/IG 31.03.2005

AMENDED SHEET


04/04/2005

International Appl. No. PCT/EP2004/005881


-40-

wherein R^1 , R^2 and R^3 are as described above and hal is preferably chloro or fluoro, or


b) reacting a compound of formula



with a compound of formula



to a compound of formula



wherein R^1 , R^2 and R^3 are as described above, and

if desired, when R^4 is other than hydrogen,

c) reacting the compound of formula IA with a compound of formula:



to a compound of formula

VB/IG 31.03.2005


AMENDED SHEET

04/04/2005

67

International Appl. No. PCT/EP2004/005881

-41-



wherein R¹, R², R³ and R⁴ are as described above, and if desired,

converting the compounds obtained into pharmaceutically acceptable acid addition salts.

10. A medicament containing one or more compounds as claimed in any one of claims 1 to 7 and pharmaceutically acceptable excipients for the treatment and prevention of mGluR5 receptor mediated disorders.

11. A medicament according to claim 10 for the treatment and prevention of acute and/or chronic neurological disorders, in particular anxiety, or for the treatment of chronic and acute pain, or for the treatment of urinary incontinence.

12. A compound in accordance with any one of claims 1 to 7 as well as its pharmaceutically acceptable salt for use in the treatment or prevention of diseases.

13. The use of a compound in accordance with any one of claims 1 to 7 as well as its pharmaceutically acceptable salt for the manufacture of medicaments for the treatment and prevention of mGluR5 receptor mediated disorders.

14. The use according to claim 12 for the manufacture of medicaments for the treatment and prevention of acute and/or chronic neurological disorders, in particular anxiety, or for the treatment of chronic and acute pain, or for the treatment of urinary incontinence.

15. The invention as hereinbefore described.

VB/IG 31.03.2005

AMENDED SHEET

04/04/2005

62


ANEXO EXPLICATIVO DE MODIFICACIONES A LAS REIVINDICACIONES

En ejercicio del derecho conferido por el Artículo 28 numeral 1 del Tratado de Cooperación en materia de Patentes PCT, atentamente me permito informar a ese Despacho que el capítulo reivindicatorio tal como fue presentado originalmente en Fase Internacional ha sido modificado.

Las modificaciones realizadas se encuentran plenamente sustentadas en la descripción de la presente invención y en este sentido, no configuran una ampliación del invento o de la divulgación contenida en la solicitud presentada.

DERIVADOS DE IMIDAZOL COMO ANTAGONISTAS DEL RECEPTOR GLUTAMATO**RESUMEN-OBJETO Y FINALIDAD DE LA INVENCION**

La presente invención se refiere a derivados del imidazol que son antagonistas del receptor mGluR5, los cuales están representados por la fórmula general I,



en donde R¹, R², R³ y R⁴ son como se han definido en la descripción, a un procedimiento para la obtención de los mismos, así como también a las sales farmacéuticamente aceptables de los mismos para la elaboración de un medicamento para el tratamiento o prevención de trastornos inducidos por el receptor mGluR5, tales como trastornos neurológicos agudos y/o crónicos.